These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19912095)

  • 21. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.
    Alexander PM; Eastaugh L; Royle J; Daley AJ; Shekerdemian LS; Penny DJ
    J Paediatr Child Health; 2012 May; 48(5):395-401. PubMed ID: 22720323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of respiratory syncytial virus infection.
    Kimpen JL
    Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis.
    Panozzo CA; Stockman LJ; Curns AT; Anderson LJ
    Pediatrics; 2010 Jul; 126(1):e116-23. PubMed ID: 20547651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis for respiratory syncytial virus bronchiolitis.
    Nadal D; Berger C; Aebi C; Kind C
    Lancet; 1999 Dec; 354(9194):1997. PubMed ID: 10622321
    [No Abstract]   [Full Text] [Related]  

  • 26. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
    Feltes TF; Sondheimer HM
    Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis.
    Assad Z; Papenburg J; Ouldali N
    Lancet Child Adolesc Health; 2024 Oct; 8(10):708-709. PubMed ID: 39208834
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
    Ohler KH; Pham JT
    Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Respiratory syncytial virus].
    Tsutsumi H
    Uirusu; 2005 Jun; 55(1):77-84. PubMed ID: 16308533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bronchiolitis (RS virus infection)].
    Yamazaki T
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():151-5. PubMed ID: 12722205
    [No Abstract]   [Full Text] [Related]  

  • 32. Respiratory syncytial virus bronchiolitis: prevention and treatment.
    Faber TE; Kimpen JL; Bont LJ
    Expert Opin Pharmacother; 2008 Oct; 9(14):2451-8. PubMed ID: 18778183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High rate of indigenous bronchiolitis and palivuzumab.
    Whitehall JS; Bolisetty S; Whitehall JP; Francis F; Norton R; Patole SK
    J Paediatr Child Health; 2001 Aug; 37(4):416-7. PubMed ID: 11547779
    [No Abstract]   [Full Text] [Related]  

  • 34. RSV immunoprophylaxis: does the benefit justify the cost?
    Meissner HC; Kimberlin DW
    Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Onuzo OC
    Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory syncytial virus: how, why and what to do.
    Rodriguez R; Ramilo O
    J Infect; 2014 Jan; 68 Suppl 1():S115-8. PubMed ID: 24171820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bronchiolitis: the new American Academy of Pediatrics guidelines.
    Corsello G
    J Chemother; 2007 Oct; 19 Suppl 2():12-4. PubMed ID: 18073171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.